Innovent Biologics Management
Management criteria checks 2/4
Innovent Biologics' CEO is Michael Yu, appointed in Jan 2011, has a tenure of 13.33 years. total yearly compensation is CN¥32.96M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 6.73% of the company’s shares, worth HK$4.47B. The average tenure of the management team and the board of directors is 4 years and 4.2 years respectively.
Key information
Michael Yu
Chief executive officer
CN¥33.0m
Total compensation
CEO salary percentage | 8.8% |
CEO tenure | 13.3yrs |
CEO ownership | 6.7% |
Management average tenure | 4yrs |
Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Innovent Biologics, Inc. (HKG:1801) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 01There's Reason For Concern Over Innovent Biologics, Inc.'s (HKG:1801) Massive 27% Price Jump
Feb 28Are Investors Undervaluing Innovent Biologics, Inc. (HKG:1801) By 33%?
Jan 12Innovent Biologics, Inc.'s (HKG:1801) Price Is Out Of Tune With Revenues
Dec 25An Intrinsic Calculation For Innovent Biologics, Inc. (HKG:1801) Suggests It's 34% Undervalued
Sep 11Is There An Opportunity With Innovent Biologics, Inc.'s (HKG:1801) 50% Undervaluation?
Jun 04Benign Growth For Innovent Biologics, Inc. (HKG:1801) Underpins Its Share Price
May 14Innovent Biologics, Inc. (HKG:1801) Shares Could Be 50% Below Their Intrinsic Value Estimate
Dec 27CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -CN¥1b |
Sep 30 2023 | n/a | n/a | -CN¥1b |
Jun 30 2023 | n/a | n/a | -CN¥1b |
Mar 31 2023 | n/a | n/a | -CN¥2b |
Dec 31 2022 | CN¥33m | CN¥3m | -CN¥2b |
Sep 30 2022 | n/a | n/a | -CN¥2b |
Jun 30 2022 | n/a | n/a | -CN¥3b |
Mar 31 2022 | n/a | n/a | -CN¥3b |
Dec 31 2021 | CN¥26m | CN¥3m | -CN¥3b |
Sep 30 2021 | n/a | n/a | -CN¥2b |
Jun 30 2021 | n/a | n/a | -CN¥1b |
Mar 31 2021 | n/a | n/a | -CN¥1b |
Dec 31 2020 | CN¥105m | CN¥3m | -CN¥998m |
Sep 30 2020 | n/a | n/a | -CN¥1b |
Jun 30 2020 | n/a | n/a | -CN¥2b |
Mar 31 2020 | n/a | n/a | -CN¥2b |
Dec 31 2019 | CN¥76m | CN¥3m | -CN¥2b |
Compensation vs Market: Michael's total compensation ($USD4.55M) is above average for companies of similar size in the Hong Kong market ($USD917.30K).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Yu (59 yo)
13.3yrs
Tenure
CN¥32,960,000
Compensation
Dr. De-Chao Yu, also known as Michael, Ph.D. Co-Founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Biol...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 13.3yrs | CN¥32.96m | 6.73% CN¥ 4.5b | |
Executive Director & Fund Managing Partner | less than a year | CN¥6.96m | 0.25% CN¥ 166.6m | |
President | 3.6yrs | no data | no data | |
Chief Financial Officer | less than a year | no data | no data | |
Chief People Officer & GM | 4.8yrs | no data | no data | |
Chief Commercial Officer | no data | no data | no data | |
Senior Vice President | 4.3yrs | no data | no data | |
Senior Vice President | no data | no data | no data | |
Senior Vice President | less than a year | no data | no data | |
Oncology Chief Medical Officer | less than a year | no data | no data | |
Joint Company Secretary | 5.9yrs | no data | no data | |
Joint Company Secretary | 5.9yrs | no data | no data |
4.0yrs
Average Tenure
49yo
Average Age
Experienced Management: 1801's management team is considered experienced (4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 13.3yrs | CN¥32.96m | 6.73% CN¥ 4.5b | |
Executive Director & Fund Managing Partner | no data | CN¥6.96m | 0.25% CN¥ 166.6m | |
Member of CMC Strategic Advisory Board & Independent Non-Executive Director | 8.6yrs | CN¥400.00k | 0.0028% CN¥ 1.9m | |
Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
Independent Non-Executive Director | 5.6yrs | CN¥400.00k | 0.00039% CN¥ 258.8k | |
Independent Non-executive Director | 1.9yrs | CN¥233.00k | 0.00030% CN¥ 199.1k | |
Member of CMC Strategic Advisory Board | no data | no data | no data | |
Member of CMC Strategic Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 5.6yrs | CN¥400.00k | 0.00033% CN¥ 219.0k | |
Member of CMC Strategic Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
Member of Scientific Advisory Board | 2.8yrs | no data | no data |
4.2yrs
Average Tenure
67yo
Average Age
Experienced Board: 1801's board of directors are considered experienced (4.2 years average tenure).